Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma
Skin Cancer

Interventions: Drug: Cisplatin, Vinblastine, Temozolomide

First Posted Date: 2009-04-22

Last Posted Date: 2015-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT00885534

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Phase 1

Completed

Conditions: Bone Marrow, Sympathetic Nervous System
Neuroblastoma

Interventions: Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8

First Posted Date: 2009-04-07

Last Posted Date: 2019-01-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 71

Registration Number: NCT00877110

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Vulvar Cancer
Vaginal Cancer
Ovarian Cancer
Uterine Cancer

Interventions: Behavioral: online platform WEBCORE

First Posted Date: 2009-03-27

Last Posted Date: 2018-10-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 120

Registration Number: NCT00870233

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

Not Applicable

Recruiting

Conditions: Glioma
Brain Cancer

Interventions: Procedure: MRI and advanced MRI sequences

First Posted Date: 2009-03-27

Last Posted Date: 2024-10-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 135

Registration Number: NCT00870129

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Radiation: intensity modulated radiation therapy
Drug: RAD001 (everolimus) + Cisplatin

First Posted Date: 2009-03-10

Last Posted Date: 2013-07-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT00858663

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Castration-resistant, Metastatic

Interventions: Other: testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride

First Posted Date: 2009-03-02

Last Posted Date: 2015-10-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT00853697

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Urinary Bladder

Interventions: Drug: Sunitinib
Drug: Gemcitabine
Drug: cisplatin

First Posted Date: 2009-02-19

Last Posted Date: 2016-02-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT00847015

Locations: 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States

and more 2 locations

Sorafenib and Dacarbazine in Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Leiomyosarcoma
Malignant Peripheral Nerve Sheath Tumor
Sarcoma
Synovial Sarcoma

Interventions: Drug: Sorafenib and Dacarbazine

First Posted Date: 2009-02-05

Last Posted Date: 2015-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT00837148

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors

Not Applicable

Completed

Conditions: Brain Cancer
Gliomas

Interventions: Radiation: [18F]FACBC PET and [18F]FLT PET imaging

First Posted Date: 2009-01-30

Last Posted Date: 2018-04-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT00832598

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Adolescent and Young Adult Cancer Survivors: Identity Development

Active, not recruiting

Conditions: Cancer

Interventions: Behavioral: interview
Behavioral: Focus groups
Behavioral: Questionnaire

First Posted Date: 2009-01-30

Last Posted Date: 2025-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 300

Registration Number: NCT00832325

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy